Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Should Not Be a Barrier to Allogenic HSCT

Bone Marrow Transplant; ePub 2017 Sep 4; Modi, et al

Publish date:: September 17, 2017

Older age alone should not be considered a barrier to receiving allogeneic hematopoietic stem cell transplant (HSCT) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), according to a retrospective analysis involving 159 individuals.

Participants were aged ≥60 years with AML (n=103) or MDS (n=56) who underwent allogenic HSCT between 2005 and 2014. Investigators looked at nonrelapse mortality, relapse, relapse-free survival, and overall survival 1 year after transplant. Among the results:

Grade III-IV acute graft-vs-host disease (GVHD) occurred in 21% of patients; chronic GVHD occurred in 54%.
Nonrelapse mortality, relapse-free survival, relapse rate, and overall survival were 25%, 53%, 21%, and 56%, respectively.
High disease risk index was linked with poor relapse-free and overall survival, as well as higher relapse rate.
Non-thymoglobulin-based GVHD prophylaxis, higher comorbidity index, and MDS were linked with higher nonrelapse mortality.
Age did not adversely impact nonrelapse mortality, relapse, relapse-free survival, and overall survival.

Citation:

Modi D, Deol A, Kim S, et al. Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. [Published online ahead of print September 4, 2017]. Bone Marrow Transplant. doi:10.1038/bmt.2017.182.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in AML

Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al

Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al

Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al

Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al

Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al